Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,000,554 papers from all fields of science
Search
Sign In
Create Free Account
nebicapone
Known as:
1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Acetophenones
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.
Daniela Gonçalves
,
G. Alves
,
P. Soares-da-Silva
,
A. Falcão
Analytica Chimica Acta
2012
Corpus ID: 23686271
Review
2012
Review
2012
A Systematic Review of Catechol-O-Methyltransferase Inhibitors: Efficacy and Safety in Clinical Practice
S. Z. Marsala
,
M. Gioulis
,
R. Ceravolo
,
M. Tinazzi
Clinical neuropharmacology
2012
Corpus ID: 2585742
&NA;Catechol-O-methyltransferase (COMT) inhibitors are drugs commonly used in the management of patients with Parkinson disease…
Expand
2011
2011
In‐vivo evaluation of prolonged release bilayer tablets of anti‐Parkinson drugs in Göttingen minipigs
J. P. Sousa e Silva
,
J. Lobo
,
M. Bonifácio
,
Rita Machado
,
A. Falcão
,
P. Soares-da-Silva
The Journal of pharmacy and pharmacology
2011
Corpus ID: 43054739
Objectives Patients with Parkinson's disease can benefit from controlled released levodopa dosage forms since there is a clear…
Expand
Review
2010
Review
2010
Toxicology and safety of COMT inhibitors.
K. Haasio
International review of neurobiology
2010
Corpus ID: 21860089
Review
2010
Review
2010
Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
S. Kaakkola
International review of neurobiology
2010
Corpus ID: 883048
2010
2010
A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease
J. Ferreira
,
O. Rascol
,
+5 authors
P. Soares-da-Silva
CNS Neuroscience & Therapeutics
2010
Corpus ID: 24450527
To determine the efficacy, safety and tolerability of nebicapone, a new catechol‐O‐methyltransferase inhibitor for the treatment…
Expand
2008
2008
Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease
J. Ferreira
,
L. Almeida
,
+12 authors
P. Soares-da-Silva
Clinical neuropharmacology
2008
Corpus ID: 206126364
Objective: To investigate the effects of nebicapone, a new catechol-O-methyltransferase (COMT) inhibitor, on levodopa…
Expand
Review
2007
Review
2007
Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.
M. Bonifácio
,
P. Palma
,
L. Almeida
,
P. Soares-da-Silva
CNS drug reviews
2007
Corpus ID: 45250591
Parkinson's disease (PD) is a neurological disorder characterized by the degeneration of dopaminergic neurons, with consequent…
Expand
2006
2006
Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation
A. Loureiro
,
M. Bonifácio
,
C. Fernandes‐Lopes
,
L. Almeida
,
L. Wright
,
P. Soares-da-Silva
Drug Metabolism And Disposition
2006
Corpus ID: 24470963
Nebicapone (BIA 3-202; 1-[3,4-dihydroxy-5-nitrophenyl]-2-phenylethanone), a novel catechol-O-methyltransferase inhibitor, is…
Expand
2002
2002
Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor.
D. Learmonth
,
A. P. Freitas
Bioconjugate chemistry
2002
Corpus ID: 19989210
BIA 3-202, 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenylethanone 3, is a novel, reversible, and tight-binding peripheral inhibitor of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE